• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Osteoboost Health Raises $8M for FDA-Cleared Bone Density Device

by Jasmine Pennic 04/15/2026 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Osteoboost Health Raises $8M for FDA-Cleared Bone Density Device

What You Should Know

  • The Raise: Osteoboost Health has closed an $8M financing round led by Ambit Health Ventures, with participation from Emmeline Ventures, Disrupt Health Impact Fund, Esplanade Ventures, and Portfolia.
  • The Device: The FDA-cleared “Osteoboost” device is a wearable belt worn low around the hips. It delivers targeted, precisely calibrated vibration therapy directly to the lumbar spine and hips (the regions most vulnerable to fracture).
  • The Clinical Gap: The device targets osteopenia, the precursor to osteoporosis. Nearly 44 million Americans live with low bone density, and bone loss accelerates rapidly during menopause. Currently, there are no approved drug therapies for osteopenia, leaving patients with few proactive options beyond calcium and exercise.
  • The Science: The vibration therapy was inspired by NASA-funded research. In a double-blinded clinical trial, patients who used the device 3 times per week for 30-minute sessions over a 12-month period slowed bone density loss by 85% in the spine and 55% in the hips.

A First-of-Its-Kind Solution for Osteopenia

While nearly 54 million Americans live with osteoporosis or low bone density, few proactive options exist for women during menopause, when bone loss accelerates rapidly. Osteoboost is a class II prescription medical device and stands as the first and only FDA-cleared, non-drug treatment clinically proven to treat low bone density in postmenopausal women with osteopenia.

“The cost of osteoporosis to society is enormous, but this is not a condition that begins at diagnosis,” said Laura Yecies, CEO of Osteoboost Health. “This funding advances Osteoboost’s vision of building a complete bone health solution and changing the trajectory of bone health for millions.”

Proven Clinical Impact

The device, worn around the hips, delivers precisely calibrated, low-magnitude vibration therapy to the lumbar spine and hips—the areas most vulnerable to fracture. Inspired by NASA-funded research, a double-blinded clinical trial at the University of Nebraska Medical Center proved the device’s efficacy:

  • Spine: Slowed bone density loss by 85%.
  • Hips: Slowed bone density loss by 55%.
  • Usage: Results achieved by patients using the device at least three times per week for 30-minute sessions.

Addressing an Underfunded Market

The financing comes at a critical time for women’s health. Despite the immense need, a 2026 World Economic Forum report highlighted that the sector receives only 6% of private healthcare capital. Osteoboost addresses a significant “gap” in care for peri- and post-menopausal women who have osteopenia but do not yet qualify for approved drug therapies.

A Comprehensive Ecosystem for Bone Health

Beyond the wearable device, the company is building a holistic ecosystem through Wellen by Osteoboost. This asynchronous video training platform, developed by physical therapists, has shown remarkable results:

  • Strength: Users improved lower-body strength by 22.8% after 18 sessions.
  • Fall Risk: Nearly 80% of participants at elevated risk improved to average or above-average levels.

Osteoboost, which was named one of TIME’s Best Inventions of 2025, has already been prescribed by more than 2,500 unique physicians across leading academic medical centers since shipping began in May 2025. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |